The sessions looking at more detailed analysis on toxicity of CAR-T were especially interesting. Of course, all these sessions that were dedicated in some ways to patients and looking at patient-related outcomes were also very interesting. And of course, all the development being made by the academia regarding CAR T-cell outside, let’s say pharma companies, I think that they were also very interesting...
The sessions looking at more detailed analysis on toxicity of CAR-T were especially interesting. Of course, all these sessions that were dedicated in some ways to patients and looking at patient-related outcomes were also very interesting. And of course, all the development being made by the academia regarding CAR T-cell outside, let’s say pharma companies, I think that they were also very interesting. I would say that in general, the meeting that unfortunately had to be done in a virtual format this year, and really it’s already a classic. I think that it has become a classic meeting, having an excellent overview of CAR T-cells, not only from a European perspective but of course from a global perspective.